Postinfarction left ventricular remodeling: A pathophysiological and therapeutic review

Cardiovascular Drugs and Therapy

Volumn 14, Issue 3, 2000, Pages 243-252

  Yousef, Zaheer Raza ^a,b   Redwood, Simon Robert ^b   Marber, Michael Stephen ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYBRID PROTEIN; NATRIURETIC FACTOR; OMAPATRILAT; PENTOXIFYLLINE; RENIN; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

BRADYCARDIA; CLINICAL TRIAL; DRUG USE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REPERFUSION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MYOCARDIAL INFARCTION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0033939770     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007879205916     Document Type: Review

References (79)

1. 1. Coronary Heart Disease Statistics. British Heart Foundation/Coronary Prevention Group Statistics Database, 1995.
2. 2. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s: Evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22(Suppl. A):3A-5A.
3. 3. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, Grobbee DE. The epidemiology of heart failure. Eur Heart J 1997;18:208-225.
4. 4. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 1997;278:2093-2098.
5. 5. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:5:1124-1136.
6. 6. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R. Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation 1991;83:3:739-746.
7. 7. The ISIS-2 Collaborative Group. Second International Study of Infarct Survival. Lancet 1988;2:349-360.
8. 8. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;329: 383-389.
9. 9. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: Mechanisms and management. Am J Cardiol 1991;68(Suppl. D):1-6D.
10. 10. Baur LH, Schipperheyn JJ, van der Wall EE, et al. Regional myocardial shape alterations in patients with anterior myocardial infarction. Int J Card Imag 1996;12:2:89-96.
11. 11. Stillwell GK. The Law of Laplace. Some clinical applications. Mayo Clin Proc 1973;48:12:863-869.
12. 12. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:1:44-51.
13. 13. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27:6: 1281-1292.
14. 14. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997;78: 3:278-284.
15. 15. Olivetti G, Capasso JM, Sonnenblick EH, Anversa P. Side-to-side slippage of myocytes participates in ventricular wall remodeling acutely after myocardial infarction in rats. Cirs Res 1990;67:1:23-34.
16. 16. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063-3070.
17. 17. McAlpine HM, Morton JJ, Leckie B, Rumley A, Gillen G, Dargie HJ. Neuroendocrine activation after acute myocardial infarction. Br Heart J 1988;60:117-124.
18. 18. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:1:248-254.
19. 19. Sugden PH. Signalling in myocardial hypertrophy - life after calcineurin? Circ Res 1999;84:633-646.
20. 20. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
21. 21. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
22. 22. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
23. 23. The CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
24. 24. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
25. 25. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16, 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
26. 26. GISSI-3: Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
27. 27. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
28. 28. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
29. 29. Goodfriend TL, Elliot ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-1654.
30. 30. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
31. 31. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone therapy and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-575.
32. 32. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
33. 33. Weber KT. Aldosterone in heart failure. Postgrad Med 1993;93:203-207.
34. 34. Struthers AD. Ten years of natriuretic peptide research: A new dawn for their diagnostic and therapeutic use? Br Med J 1994;308:1615-1619.
35. 35. Lang CC, Struthers AD. Atrial and brain natriuretic peptides - a dual natriuretic peptide system potentially involved in circulatory homoeostasis. Clin Sci 1992;83:519-527.
36. 36. Trippodo NC, Fox M, Monticello TM, Punchal BC, Asaad MM. Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than with ACE inhibition. Circulation 1998;98(Suppl. I):4095.
37. 37. Levin ER. Endothelins. N Engl J Med 1995;333:356-363.
38. 38. Watanabe T, Suzuki N, Shimamoto N, et al. Endothelin in myocardial infarction. Nature 1990;344:114.
39. 39. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-1982.
40. 40. Packer M, Caspi A, Charlon V, et al. Multi-centre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial.Circulation 1998;98(Suppl. I):12.
41. 41. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-554.
42. 42. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994;331:468-469.
43. 43. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: The cytokine hypothesis. J Card Failure 1996;2:243-249.
44. 44. Levine B, Kaiman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
45. 45. Maury CPJ, Teppo AM. Circulating levels of tumour necrosis factor-α (cachectin) in myocardial infarction. J Int Med 1989;225:333-336.
46. 46. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Investig 1993;92:2303-2312.
47. 47. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375-1381.
48. 48. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble p75 tumour necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-3226.
49. 49. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-1093.
50. 50. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80(Suppl. A):15-25L.
51. 51. Simpson PC. Role of proto-oncogenes in myocardial hypertrophy. Am J Cardiol 1988;62 (Suppl. G):13G-19G.
52. 52. Glennon PE, Sugden PH, Poole-Wilson PA. Cellular mechanisms of cardiac hypertrophy. Br Heart J 1995;73:496-499.
53. 53. Adinolfi A, Adinolfi M, Lessof MH. Alpha-feto-protein during development and in disease. J Med Gen 1975;12:138-151.
54. 54. Agah R, Kirshenbaum LA, Abdellatif M, et al. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium in vivo. J Clin Invest 1997;100:2722-2728.
55. 55. Hunter JJ, Tanaka N, Rockman HA, Ross J, Jr., Chein KR. Ventricular overexpression of the MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995;270:23171-23178.
56. 56. Sakata Y, Hoit BD, Liggett SB, Walsh RA, Dorn GW. Decompensation of pressure-overload hypertrophy in Gaq-overexpressing mice. Circulation 1998;97:1488-1495.
57. 57. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997;100:2189-2195.
58. 58. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
59. 59. Sussman MA, Lim HW, Gude N, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998;281:1690-1693.
60. 60. Force T, Hajjar R, Rosenzweig A, Choukroun G. Calcineurin inhibitors and cardiac hypertrophy. Lancet 1999;353:1290-1292.
61. 2-terminal kinases. J Clin Invest 1999;104:391-398.
62. 62. Olivetti G, Capasso JM, Meggs LG, Sonnenblich EH, Anversa P. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991;68:856-869.
63. 63. Wollert KC, Taga T, Saito M, et al. Cardiotrophin activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series via gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem 1996;271:9535-9545.
64. 64. Decock JBJ, Gillespie-Brown J, Parker PJ, Sugden PH, Fuller SJ. Classical, novel and atypical isoforms of PKC stimulate ANF- and TRE/AP-1-regulated-promoter activity in ventricular cardiomyocytes. FEBS Letts 1994;356:275-278.
65. 65. Pennica D, Shaw KJ, Swanson TA, et al. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem 1995;270:10915-10922.
66. 66. Pan J, Fukuda K, Saito M, et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1999;84:1127-1136.
67. 67. Morimoto T, Hasegawa K, Kaburagi S, et al. GATA-5 is involved in leukemia inhibitory factor-responsive transcription of the beta-myosin heavy chain gene in cardiac myocytes. J Biol Chem 1999;274:12811-12818.
68. 68. Betz UAK, Bloch W, Van den Broek M, et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med 1998;188:1955-1965.
69. 69. Ostrom RS, Insel PA. Caveolar microdomains of the sarcolemma. Compartmentation of signalling molecules comes of age. Circ Res 1999;84:1110-1112.
70. 70. Schillace RV, Scott JD. Organisation of kinases, phosphatases and receptor signaling complexes. J Clin Invest 1999;103:761-765.
71. 71. Pawson T, Saxton TM. Signaling networks - Do all roads lead to the same gene? Cell 1999;97:675-678.
72. 72. Vannan MA, Taylor DJ. Ventricular remodelling after myocardial infarction. Br Heart J 1992;68:3:257-259.
73. 73. Van Vliet BN, Chafe LL, Montani JP. Contribution of baroreceptors and chemoreceptors to ventricular hypertrophy produced by sino-aortic denervation in rats. J Physiol 1999;516:885-895.
74. 74. Marber MS, Brown DL, Kloner RA. The Open Artery Hypothesis: To open, or not to open, that is the question. Eur Heart J 1996;17:505-509.
75. 75. Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987;75:299-306.
76. 76. White HD, Cross DB, Elliot JM, Norris RM, Yee TW. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994;89:61-67.
77. 77. de Bono DP for the SWIFT investigators (Should We Intervene Following Thrombolysis?) Trial Study Group. SWIFT trial of delayed elective intervention v. conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. Br Med J 1991;302:555-560.
78. 78. Williams DO, Braunwald E, Knatterud GK, et al. For the TIMI Investigators. One-year results of the Thrombolysis In Myocardial Infarction investigation (TIMI) phase II trial. Circulation 1992;85:533-542.
79. 79. Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation 1998;98:2377-2382.